Sana Biotechnology SANA 深 沪
等待开盘 12-17 09:30:00 美东时间
5.035
-0.045
-0.89%
华盛通- 最 高5.29
- 今 开5.00
- 成交量 232.20万股
- 最 低 4.91
- 昨 收 5.08
- 总市值 13.39亿
- 52周最高 7.30
- 市盈率 静 --
- 换手率 0.87%
- 52周最低 1.26
- 委 比 -81.80%
- 总股本 2.66亿
- 历史最高 44.60
- 量 比 1.03
- 振 幅 7.48%
- 历史最低 1.26
- 每 手 1
- 风险率 1.09%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Sana Biotechnology Says Nature Biotechnology Publishes Journal Article Titled "In Vivo Gene Editing Of Human Hematopoietic Stem And Progenitor Cells Using Envelope-Engineered Virus-Like Particles"
Data Demonstrate Potent in vivo Gene Editing of Hematopoietic Stem Cells (HSCs) in the Bone Marrow with Systemic Delivery in Preclinical Murine Models Using Fusogen Technology Broadens Application of Fusogen
12-08 22:05
美股牛股 | Arrowhead制药飙升23%，行业首个微粒血症商用药物获FDA批准；DeFi大涨20%
Arrowhead制药飙升23%，行业首个微粒血症商用药物获FDA批准，最新财报强劲超预期；DeFi大涨20%，公司宣布QCAD数字信托获批为加拿大首个合规的加元稳定币>>
11-27 16:04
Sana Biotechnology to Present at December 2025 Investor Conferences
Sana Biotechnology, Inc. will webcast presentations at Citi’s 2025 Global Healthcare Conference on December 2 and the 8th Annual Evercore Healthcare Conference on December 3. CEO Steve Harr will provide business updates. The webcasts and replays are available on Sana’s Investor Relations page.
11-24 21:05
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 17:17
Sana暂停开发同种异体CAR-T
当下，CAR细胞疗法的下一代开发策略主要分为两个路线，一个是发展已久的异体来源的“现货型”、一个是异军突起的in vivo（体内）。但就目前的形势来看，无论是投...
11-10 12:31
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 10:22
HC Wainwright & Co. Maintains Buy on Sana Biotechnology, Lowers Price Target to $9
HC Wainwright & Co. analyst Emily Bodnar maintains Sana Biotechnology (NASDAQ:SANA) with a Buy and lowers the price target from $11 to $9.
11-07 19:37
Sana Biotechnology Q3 Adj. EPS $(0.15) Beats $(0.18) Estimate
Sana Biotechnology (NASDAQ:SANA) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.18) by 16.67 percent. This is a 44.44 percent increase over losses of $(0.27) per share
11-07 06:13
美股大行评级 | 最高350美元！16家大行上调谷歌目标价！Meta遭12家大行下调目标价；潜在涨幅1456.29%！NRX Pharmaceuticals获Ascendiant Capital升目标价至47美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从46美元升至47美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从27美元升至31美元
10-31 10:25
Citizens Maintains Market Outperform on Sana Biotechnology, Raises Price Target to $8
Citizens analyst Reni J. Benjamin maintains Sana Biotechnology (NASDAQ:SANA) with a Market Outperform and raises the price target from $5 to $8.
10-30 20:55
